Andreas Kjær (scientist)

From Wikipedia, the free encyclopedia
(Redirected from Draft:Andreas Kjaer)
For the politician, see Andreas Kjær.
Andreas Kjær
Professor Andreas Kjaer headshot
Born(1963-04-12)April 12, 1963
Copenhagen, Denmark
NationalityDanish
AwardsERC advanced grant (2014)
Pasteur Prize (2011)
August Krogh Prize (2006)
Scientific career
FieldsNuclear Medicine, Molecular Imaging, Positron Emission Tomography (PET), PET/MR, Theranostics, Radionuclide therapy
InstitutionsUniversity of Copenhagen & Rigshospitalet, the National University Hospital

Andreas Kjær (born April 12, 1963) is a Danish physician-scientist and European Research Council (ERC) advanced grantee.[1] He is professor at the University of Copenhagen and chief physician at Rigshospitalet, the National University Hospital of Denmark. He is board certified in Nuclear Medicine and his research is focused on molecular imaging with PET and PET/MRI and targeted radionuclide therapies (theranostics) in cancer. His achievements include development of several new PET tracers that have reached first-in-human clinical use. He has published more than 400 peer-review articles, filed 10 patents, supervised more than 40 PhD students and received numerous prestigious scientific awards over the years. He is a member of the Danish Academy of Technical Sciences[2]

Education and employment[edit]

Professor Kjær received his MD degree from the University of Copenhagen in 1989 and the same year he received the United States ECFMG license as MD. In 1994 he obtained the PhD degree,[3] in 1996 the DMSc degree[4] and in 2000 he was board certified as specialist in Nuclear Medicine.[5] He was appointed full professor and chief physician in 2003. He has been a visiting scientist at Salk Institute (La Jolla) and Emory University (Atlanta). He is currently director of the PhD program for Medical & Molecular Imaging at University of Copenhagen.[6] He obtained the MBA (executive) degree from Copenhagen Business School in 1997 and participated in "Leading the virtual company" program at Harvard Business School (Boston) from 2013-14. He also served as medical officer in the Royal Danish Navy (first lieutenant 1989, lieutenant commander 1994).

Honors, awards and positions of trust[edit]

Kjær received numerous awards over the years. Examples include the August Krogh Prize[7] (Organization of Danish Medical Societies, 2006), Great Prize for Scientific Achievements (Scandinavian Society of Clinical Physiology and Nuclear Medicine, 2007), Global Excellence in Health Prize (2010) [8] and the Pasteur Prize (Danish National Advanced Technology Foundation, 2011).[9] In 2014 he was awarded an ERC advanced grant [10] and in 2015 he was appointed member of the Danish Academy of Technical Sciences.[11] He served as president of the Scandinavian Society for Clinical Physiology and Nuclear Medicine (SSCPNM) 2006-12 [12] and currently is editor-in-chief of Diagnostics (Basel)[13] as well as on advisory boards and committees.

Research focus and major contributions[edit]

Kjær's research has focused on translational molecular imaging in with PET and PET/MRI and on development of targeted radionuclide therapies (theranostics) for use in precision medicine in cancer. In addition, the use of molecular imaging for study of pathophysiology in other diseases, e.g. atherosclerosis, has been a major focus. Notable achievements of his research group include development of several new PET tracers that have reached first-in-human clinical use. Examples include first-in-humans with urokinase plasminogen activator receptor (uPAR)-PET,[14] a marker of cancer aggressiveness (68Ga-NOTA-AE105 and 64Cu-DOTA-AE105)[15][16] and first-in-humans with 64Cu-DOTATATE for somatostatin receptor imaging in neuroendocrine tumors.[17][18][19][20] His group also demonstrated the prognostic value of FDG-PET in neuroendocrine tumor patients[21][22] and were first to combine 13C-hyperpolarized MRSI and PET on a clinical PET/MRI scanner, a technique they named hyperPET.[23][24] Recently his group developed and demonstrated the feasibility of uPAR-targeted optical imaging for cancer surgery guidance[25]

References[edit]

  1. ^ Biography in: Kraks Blå Bog 2017-18 (included since 2008/09) (1st ed.). Gads Forlag. 2017. ISBN 9788712055044.
  2. ^ "Danish Academy of Technical Sciences". www.atv.dk. Retrieved 23 August 2017.
  3. ^ Kjær, Andreas (1994). Stress-induced release of pro-opiomelanocortin derived peptides: Involvement of histaminergic neurons and beta-adrenergic receptors. University of Copenhagen. pp. 1–100.
  4. ^ Kjær, Andreas (December 1996). "Neurohypophysial peptides. Histaminergic regulation and function in adenohypophysial secretion". Danish Medical Bulletin. 43 (5): 391–406. PMID 8960813.
  5. ^ "Danish registry of health professionals [enter "Andreas Kjær"]". Danish Patient Safety Authority. Retrieved 21 August 2017.
  6. ^ "Graduate program of Medical and Molecular Imaging at University of Copenhagen". 2016-12-08. Retrieved 2017-08-21.
  7. ^ "Novo Nordisk Foundation: the Marie and August Krogh Prize". Archived from the original on 2017-09-03. Retrieved 2017-06-11.
  8. ^ "Global Excellence winners 2010" (PDF). Retrieved 2017-06-11.
  9. ^ "PasteurPrize 2011". Retrieved 2017-06-29.
  10. ^ "Ministry of Higher Education and Science: Danish ERC advanced grantees 2014". Retrieved 2017-06-11.
  11. ^ "Danish Academy of Technical Sciences - new members 2015". Archived from the original on 2017-11-16. Retrieved 2017-06-11.
  12. ^ "Scandinavian Society of Clinical Physiology and Nuclear Medicine". www.sscpnm.com.
  13. ^ "Diagnostics (Basel) Editor-in-Chief: Andreas Kjaer". Retrieved 2017-06-29.
  14. ^ Vasdev, Neil; Alavi, Abass (July 2017). "Novel PET radiotracers with potential clinical applications". PET Clinics. 12 (3): 269–372. doi:10.1016/j.cpet.2017.04.002. PMID 28576174.
  15. ^ Persson, M; Skovgaard, D; Brandt-Larsen, M; Christensen, C; Madsen, J; Nielsen, CH; Thurison, T; Klausen, TL; Holm, S; Loft, A; Berthelsen, AK; Ploug, M; Pappot, H; Brasso, K; Kroman, N; Højgaard, L; Kjaer, A (2015). "First-in-human uPAR PET: Imaging of cancer aggressiveness". Theranostics. 5 (12): 1303–16. doi:10.7150/thno.12956. PMC 4615734. PMID 26516369.
  16. ^ Skovgaard, D.; Persson, M.; Brandt-Larsen, M.; Christensen, C.; Madsen, J.; Klausen, T. L.; Holm, S.; Andersen, F. L.; Loft, A.; Berthelsen, A. K.; Pappot, H.; Brasso, K.; Kroman, N.; Højgaard, L.; Kjaer, A. (2017). "Safety, Dosimetry, and Tumor Detection Ability of 68Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging". Journal of Nuclear Medicine. 58 (3): 379–386. doi:10.2967/jnumed.116.178970. PMID 27609788.
  17. ^ Kjaer, Andreas; Højgaard, Liselotte; Benzon, Eric von; Holm, Søren; Klausen, Thomas Levin; Elema, Dennis; Rasmussen, Palle; Binderup, Tina; Loft, Annika; Berthelsen, Anne Kiil; Oturai, Peter; Mortensen, Jann; Knigge, Ulrich; Pfeifer, Andreas (August 2012). "Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study". Journal of Nuclear Medicine. 53 (8): 1207–1215. doi:10.2967/jnumed.111.101469. PMID 22782315.
  18. ^ Kjaer, Andreas; Højgaard, Liselotte; Benzon, Eric von; Elema, Dennis; Rasmussen, Palle; Langer, Seppo W.; Berthelsen, Anne Kiil; Loft, Annika; Oturai, Peter; Mortensen, Jann; Binderup, Tina; Knigge, Ulrich; Pfeifer, Andreas (June 2015). "64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients". Journal of Nuclear Medicine. 56 (6): 847–854. doi:10.2967/jnumed.115.156539. PMID 25952736. Retrieved 2017-06-29.
  19. ^ "Outstanding JNM Articles for 2015 [Editor's Choice Award 2015 for 64Cu-DOTATATE publication]" (PDF). Journal of Nuclear Medicine. 57: 15N. 2016. Retrieved 9 September 2017.
  20. ^ Bodei, L; Sundin, A; Kidd, M; Prasad, V; Modlin, IM (2015). "The status of neuroendocrine tumor imaging: from darkness to light?". Neuroendocrinology. 101 (1): 1–17. doi:10.1159/000367850. PMID 25228173.
  21. ^ Ray, K (April 2010). "Research Highlight: FDG-PET predicts neuroendocrine tumor survival". Nature Reviews Clinical Oncology. 7 (4): 184–c1, author reply 184–c2. doi:10.1038/nrclinonc.2010.26. PMID 20380023. S2CID 7642508.
  22. ^ Binderup, Tina; Knigge, Ulrich; Loft, Annika; Federspiel, Birgitte; Kjaer, Andreas (2010). "18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors" (PDF). Clinical Cancer Research. 16 (3): 978–985. doi:10.1158/1078-0432.CCR-09-1759. PMID 20103666. S2CID 14298210. Retrieved 2017-06-29.
  23. ^ Gutte, H.; Hansen, A. E.; Larsen, M. M.; Rahbek, S.; Henriksen, S. T.; Johannesen, H. H.; Ardenkjaer-Larsen, J.; Kristensen, A. T.; Højgaard, L.; Kjær, A. (2015). "Simultaneous Hyperpolarized 13C-Pyruvate MRI and 18F-FDG PET (HyperPET) in 10 Dogs with Cancer". Journal of Nuclear Medicine. 56 (11): 1786–92. doi:10.2967/jnumed.115.156364. PMID 26338899. Retrieved 2017-06-29.
  24. ^ Albinus, Niels-Bjorn (June 6, 2014). "Sick dogs test danish world premiere". Dagens Medicin (in Danish) (13): 1, 6–7.
  25. ^ Christensen, A; Juhl, K; Persson, M; Charabi, BW; Mortensen, J; Kiss, K; Lelkaitis, G; Rubek, N; von Buchwald, C; Kjær, A (2017). "uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model". Oncotarget. 8 (9): 15407–15419. doi:10.18632/oncotarget.14282. PMC 5362495. PMID 28039488.


External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Andreas_Kjær_(scientist)&oldid=1188078745"